Vor Biopharma (VOR) Net Cash Flow (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Net Cash Flow data on file, last reported at -$226.6 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 610.34% year-over-year to -$226.6 million in Q1 2026; TTM through Mar 2026 was $117.6 million, a 2213.22% increase from a year earlier, with the FY2025 full-year figure at $312.3 million, up 517.31% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$226.6 million, down from $236.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for VOR reached as high as $236.0 million in Q4 2025 and fell as low as -$226.6 million in Q1 2026.
• Historically, Net Cash Flow has averaged $2.8 million across 5 years, with a median of -$10.2 million in 2023.
• Across the five-year window, Net Cash Flow jumped 709.66% in 2025 and plunged 610.34% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at -$3.1 million in 2022, then sank by 337.87% to -$13.7 million in 2023, then jumped by 313.31% to $29.2 million in 2024, then soared by 709.66% to $236.0 million in 2025, then tumbled by 196.01% to -$226.6 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$226.6 million in Q1 2026, $236.0 million in Q4 2025, and -$32.4 million in Q3 2025.